CA2470016A1 - Produit antibiotique, son utilisation et sa formulation - Google Patents

Produit antibiotique, son utilisation et sa formulation Download PDF

Info

Publication number
CA2470016A1
CA2470016A1 CA002470016A CA2470016A CA2470016A1 CA 2470016 A1 CA2470016 A1 CA 2470016A1 CA 002470016 A CA002470016 A CA 002470016A CA 2470016 A CA2470016 A CA 2470016A CA 2470016 A1 CA2470016 A1 CA 2470016A1
Authority
CA
Canada
Prior art keywords
dispersion
eudragit
pellets
antibiotic
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002470016A
Other languages
English (en)
Inventor
Edward M. Rudnic
James D. Isbister
Donald J. Treacy, Jr.
Sandra E. Wassink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MiddleBrook Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/027,866 external-priority patent/US6663890B2/en
Priority claimed from US10/027,366 external-priority patent/US6667057B2/en
Priority claimed from US10/027,609 external-priority patent/US6669948B2/en
Priority claimed from US10/028,595 external-priority patent/US6663891B2/en
Priority claimed from US10/028,590 external-priority patent/US6730320B2/en
Priority claimed from US10/027,837 external-priority patent/US6667042B2/en
Application filed by Individual filed Critical Individual
Publication of CA2470016A1 publication Critical patent/CA2470016A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne un produit antibiotique comprenant au moins trois formes dosifiées, chacune de ces formes dosifiées présentant un profil de libération différent, la concentration sérique maximale C¿max? de ce produit antibiotique étant atteinte en moins de douze heures environ. Dans un mode de réalisation, ce produit comprend une forme dosifiée à libération immédiate ainsi qu'au moins deux formes dosifiées à libération retardée, chacune de ces formes dosifiées présentant un profil de libération différent et atteignant une C¿max? à des instants différents.
CA002470016A 2001-12-20 2002-12-20 Produit antibiotique, son utilisation et sa formulation Abandoned CA2470016A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US10/028,595 2001-12-20
US10/027,866 US6663890B2 (en) 2000-02-24 2001-12-20 Metronidazole antibiotic product, use and formulation thereof
US10/027,366 2001-12-20
US10/027,366 US6667057B2 (en) 2000-02-24 2001-12-20 Levofloxacin antibiotic product, use and formulation thereof
US10/028,590 2001-12-20
US10/027,609 US6669948B2 (en) 2000-02-24 2001-12-20 Antibiotic product, use and formulation thereof
US10/028,595 US6663891B2 (en) 2000-02-24 2001-12-20 Erythromyacin antibiotic product, use and formulation thereof
US10/027,837 2001-12-20
US10/027,866 2001-12-20
US10/028,590 US6730320B2 (en) 2000-02-24 2001-12-20 Tetracycline antibiotic product, use and formulation thereof
US10/027,609 2001-12-20
US10/027,837 US6667042B2 (en) 2000-02-24 2001-12-20 Fluroquinilone antibiotic product, use and formulation thereof
PCT/US2002/040809 WO2003086344A1 (fr) 2001-12-20 2002-12-20 Produit antibiotique, son utilisation et sa formulation

Publications (1)

Publication Number Publication Date
CA2470016A1 true CA2470016A1 (fr) 2003-10-23

Family

ID=29255716

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002470016A Abandoned CA2470016A1 (fr) 2001-12-20 2002-12-20 Produit antibiotique, son utilisation et sa formulation

Country Status (5)

Country Link
EP (1) EP1465591A1 (fr)
JP (1) JP2005523309A (fr)
AU (1) AU2002359768A1 (fr)
CA (1) CA2470016A1 (fr)
WO (1) WO2003086344A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
WO2005009365A2 (fr) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Produit antibiotique, son utilisation et sa formulation
PT1883396E (pt) 2005-05-18 2013-10-08 Centre Nat Rech Scient Administração colónica de adsorventes
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
JP5318400B2 (ja) * 2006-11-20 2013-10-16 第一三共株式会社 レボフロキサシン含有錠剤
JP5788142B2 (ja) * 2006-12-04 2015-09-30 シオノギ インコーポレイテッド 変性放出アモキシシリン製剤
US20130259947A1 (en) * 2010-11-29 2013-10-03 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
GB201210184D0 (en) * 2012-06-11 2012-07-25 Univ Leuven Kath Formulations of metronidazole for the treatment of pouchitis
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011692A (en) * 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT

Also Published As

Publication number Publication date
JP2005523309A (ja) 2005-08-04
AU2002359768A1 (en) 2003-10-27
EP1465591A1 (fr) 2004-10-13
WO2003086344A1 (fr) 2003-10-23

Similar Documents

Publication Publication Date Title
US6730320B2 (en) Tetracycline antibiotic product, use and formulation thereof
US8889187B2 (en) Once a day amoxicillin product comprising immediate and delayed release dosage forms
US6669948B2 (en) Antibiotic product, use and formulation thereof
US6667057B2 (en) Levofloxacin antibiotic product, use and formulation thereof
US6663891B2 (en) Erythromyacin antibiotic product, use and formulation thereof
US6667042B2 (en) Fluroquinilone antibiotic product, use and formulation thereof
US6663890B2 (en) Metronidazole antibiotic product, use and formulation thereof
CA2494015C (fr) Produit antibiotique, utilisation et formulation associees
US6991807B2 (en) Antibiotic composition
US6638532B2 (en) Tetracycline—doxycycline antibiotic composition
US6627222B2 (en) Amoxicillin-dicloxacillin antibiotic composition
US6623758B2 (en) Cephalosporin-metronidazole antibiotic composition
US20030086969A1 (en) Ciprofoxacin-metronidazole antibiotic composition
CA2470016A1 (fr) Produit antibiotique, son utilisation et sa formulation
CA2478121A1 (fr) Composition antibiotique
PRODUCT pro? le.
AU2003218024C1 (en) Antibiotic composition

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead